International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 09 Issue: 06 | June - 2025 SJIF Rating: 8.586 ISSN: 2582-3930

Beyond Berberine: The Therapeutic Revolution of Dihydroberberine

Achal Agarwal[1,2], Pankaj Pillewan[3], Manik Chaudhuri[4],Girisha Maheshwari[4]

M R Healthcare Pvt Ltd.

Indian Herbs Extractions

Wellnesslink Pharma Services

Xplora Clinical Research Services Pvt Ltd.

*Corresponding author: achal@mrhealthcare.in

M R Healthcare Pvt Ltd. Tanda Mallu, Kashipur Road Ramnagar, Distt-Nanital (Uttarakhand), India-244715

Abstract

Dihydroberberine (DHB), a highly bioavailable and potent derivative of the alkaloid berberine, represents a significant advancement in herbal and pharmaceutical therapeutics. Although berberine has been utilized for its extensive therapeutic properties, including antidiabetic, antimicrobial, anti-inflammatory, and cardioprotective activities. The clinical efficacy of DHB is limited by its poor bioavailability and rapid metabolism. Dihydroberberine, the hydrogenated metabolite of berberine, overcomes these limitations and demonstrates enhanced intestinal absorption, improved pharmacokinetics, and superior therapeutic outcomes. This review, developed in collaboration with **M R Healthcare Pvt Ltd. and Indian Herbs Extractions**, explores the pharmacological profile, advanced extraction methods, and precise phytochemical characterization of dihydroberberine. The mechanism of DHB includes the modulation of AMP-activated protein kinase, regulation of lipid metabolism, and potent antioxidant and anti-inflammatory effects. Various studies and clinical trials have proven that DHB is more effective in the management of metabolic syndrome, type 2 diabetes and cardiovascular disorders as compared to traditional berberine. There are a number of advantages of DHB over the traditional berberine in every aspect. The paper concludes by outlining key future research directions and opportunities, advocating for broader clinical adoption and innovation of this groundbreaking phytopharmaceutical.

Keywords: Dihydroberberine, Antidiabetic, Antimicrobial, Berberine

Introduction

Over the past two decades, natural compounds have gained momentum as alternatives to pharmaceutical agents. Among these berberine has gained more popularity berberine which is an isoquinoline that has been extracted from *Berberis aristata* [1]. Berberine has been extensively studied in various studies which has proved that berberine is used to regulate blood glucose, improve lipid metabolism, modulate gut microbiome, and suppress chronic inflammation [2]. Berberine is a compound that is known for its multitherapeutic properties for lifestyle disorders such as type 2 diabetes, dyslipidemia, obesity, and non-alcoholic fatty liver disease (NAFLD) [3].

Despite its pharmacological and therapeutic effects, berberine`s widespread adoption has been hindered by the limitation of poor oral bioavailability. The absorption of berberine in the gastrointestinal tract is minimal due to its low solubility, active efflux by transporters, and extensive first-pass metabolism [4]. The recommendations of large doses of berberine were given to achieve the clinical benefits leading to gastrointestinal side effects such as bloating, constipation, and cramping. These limitations have been observed and give rise to an urgent need for a more bioavailable product which is a derivative of berberine [5]. The comparison of berberine and Dihydroberberine has been shown in **Table No.1**.

Table No. 1: Comparison of Berberine vs Dihydroberberine

Feature	Berberine	Dihydroberberine (DHB)	References
Chemical Form	Natural alkaloids derived from plants	Hydrogenated derivative/metabolite of berberine	[1]
Bioavailability	Low (estimated <1%)	High (approximately 5x greater than berberine)	[2], [28], [30]
Absorption	Poor gastrointestinal absorption; limited by efflux transporters	Superior absorption across the intestinal lining	[1], [12], [28]
First-Pass Metabolism	Extensive; reduced efficacy after liver and gut metabolism	Minimally affected due to bypass of the microbial conversion step	[3], [10]
Required Dose for Effectiveness	1,000–1,500 mg/day	100–300 mg/day (lower doses needed for the same or better effects)	[5], [31]
Onset of Action	Slower due to absorption and conversion delays	Faster therapeutic onset due to better plasma availability	[2], [29]
AMPK Activation	Yes, significant	Yes, possibly stronger activation at lower doses	[11], [36]
Lipid Regulation	Effective, particularly for LDL and triglyceride reduction	Equally or more effective, with enhanced bioactivity	[20], [21], [33]
Blood Sugar Control	Improves insulin sensitivity and lowers glucose	Comparable or superior glycemic control due to better tissue uptake	[5], [27], [40]
Gastrointestinal Side Effects	Common at high doses (bloating, constipation, cramps)	Minimal due to lower required doses	[39], [26]
Formulation Stability	Stable in capsules but poorly absorbed	Sensitive to oxidation; often encapsulated with stabilizers	[16], [17]
Conversion in Body	Converted to DHB in the gut by microbiota before systemic absorption	Directly absorbed and converted back to berberine in the bloodstream	[3], [16]
Suitability for Long-Term Use	Limited by GI side effects and compliance issues	Better tolerated, more suitable for sustained use	[7], [31], [39]

Clinical Availability	Widely available in supplements and traditional formulations	Emerging in advanced nutraceutical and functional medicine products	[4], [6], [19]

The emergence of Dihydroberberine (DHB) which is a hydrogenated metabolite of berberine that is produced by intestinal microbiota. Unlike the parent compound, DHB is better absorbed in the gut and more efficiently converted back into the active berberine in the bloodstream [6]. There were various research and clinical studies that exhibit that DHB is 5 to 10 times higher bioavailability requires lower therapeutic doses and delivers more rapid and sustained metabolic benefits with improved tolerability [7]. Dihydroberberine is formed by the reduction of quaternary nitrogen in its central ring which results in a neutral, non-ionic structure. The structure as shown in **Figure 1** is known to enhance its lipophilicity and intestinal absorption which makes it more bioavailable than its parent compound berberine [8]. Dihydroberberine is oxidized back into its active form berberine and delivers the same therapeutic benefits with improved efficacy and fewer gastrointestinal side effects [9].



Figure 1: Structure of Dihydroberberine [1]

DHB is now becoming a next-generation nutraceutical that preserves the multi-functional strengths of berberine while overcoming its significant weakness[7]. This review will discuss about pharmacodynamics, clinical applications, molecular mechanisms, and future therapeutic potential of Dihydroberberine and how this novel compound has revolutionized metabolic health management [8].

Therapeutic Edge of Dihydroberberine

Dihydroberberine is a next-generation nutraceutical and hydrogenated metabolite of berberine which is developed to limit the pharmacokinetic effect of the parent compound [9]. Berberine is a highly effective compound in modulating glucose and lipid metabolism and also suffers from low oral bioavailability due to its quaternary ammonium structure as shown in **Figure 2** [10]. But DHB has been made by overcoming these barriers through a structural modification that is the reduction of quaternary nitrogen to a neutral dihydro form and making it lipophilic and significantly more permeable across the intestinal epithelium [11]. Once it is taken and it gets inside the body, DHB is oxidized back into berberine via a cellular enzyme thus preserving its therapeutic action. This reversible action allows DHB to function as a prodrug and enhance the berberine`s delivery without making any changes in the mechanism of action [12].



Figure No.2: Key therapeutic advantages of dihydroberberine over berberine, highlighting its enhanced bioavailability, faster absorption, lower dosing, and improved tolerability.

DHB stands out as a true breakthrough in natural therapeutics due to its significantly enhanced pharmacokinetic and clinical profile. It offers 5 to 10 times greater bioavailability than berberine and it is validated in both animal studies and human pharmacokinetic trials [13]. This absorption enables lower effective dosing that ranges from 100-300 mg/day as compared to 1000-1500 mg/day. DHB also features a faster absorption rate that reaches peak plasma concentration within 1-2 hours with improved systemic exposure metrics such as AUC and C max [14]. DHB is associated with fewer gastrointestinal side effects which makes it a more tolerable option for long-term use. It is increasingly being incorporated into advanced delivery systems such as micellar, liposomal, and nano-carrier-based formulations[15]. The commercially available products in the market like GlucoVantage® and GlucoSober® are capitalizing on these benefits and show promise in the management of insulin resistance, metabolic syndrome, and even weight control [16-17]. It is more than a reformulation. It is an engineered molecule that elevates the potential of plant-based medicine through modern pharmaceutical innovation which provides a safer and more potent tool in the prevention and treatment of chronic metabolic diseases [18].

Pharmacokinetics and Bioavailability of Dihydroberberine

The most compelling advantages of Dihydroberberine lie in its dramatically improved pharmacokinetic profile as shown in **Table No. 2**. Berberine`s limitation of poor bioavailability has become a major barrier to its clinical effectiveness [19]. This limitation is attributed to its structure, poor intestinal permeability, and extensive first-pass metabolism in the liver and gut wall. In comparison to Dihydroberberine hydrogenated non-ionic structure allows significantly enhanced absorption by reduction in the first-pass degradation and superior systemic availability [20-21].

Table No. 2: Pharmacokinetic Profile of Dihydroberberine (DHB)

Pharmacokinetic Parameter	**Dihydroberberine (DHB)**	**References**
Bioavailability	5-10 x higher than berberine	[1], [2], [28], [29]
Tmax (Time to peak)	1-2 hours	[12], [35]
Cmax (Peak plasma concentration)	High	[28], [29]
AUC (Total drug exposure)	Significantly higher than Berberine	[2], [29], [41]
Absorption mechanism	Passive diffusion due to lipophilic structure	[1], [30]
Conversion in body	Oxidized to berberine in the bloodstream	[3], [16]

Effective dose (oral)	100-300 mg/day	[5], [31]
First-pass metabolism	Minimal	[10], [35]

Redox Cycling: DHB as a prodrug

After oral administration, DHB is readily available and absorbed through intestinal epithelium due to its lipophilic and neutral nature [22]. In the bloodstream, it undergoes rapid oxidation back to berberine primarily via liver and cellular mechanisms that allow DHB to serve as a prodrug that effectively delivers active berberine to the systemic circulation in a targeted manner [23]. This redox reaction bypasses the need for microbial activation in the gut which is a rate-limiting step for berberine [24].

Clinical Relevance

The pharmacokinetic advantages translate the real-world benefits that are lowering the effective dosing, reduced gastrointestinal discomfort, and more stable plasma drug levels. The DHB is well-suited for long-term management of chronic metabolic disorders that include diabetes, dyslipidemia, and obesity [25]. DHB is rapidly gaining traction in functional medicine and integrative health settings as a preferred alternative to conventional berberine supplementation [26].

Mechanism of Action

Dihydroberberine once absorbed and converted back into berberine retains and amplifies the bioactivity of its parent compound through several key molecular pathways. The enhanced bioavailability of DHB ensures that the pathways are activated more consistently and effectively at lower doses [27].

- **Activation of activated protein kinase (AMPK):** The most well-established mechanism of DHB which is considered a master regulator of cellular energy homeostasis. This activation leads to increased glucose uptake by enhancing GLUT4 translocation, inhibition of hepatic gluconeogenesis, enhanced fatty acid oxidation, and downregulation of lipogenesis. These effects have improved DHB in insulin sensitivity, reduced blood glucose levels, and supported weight management [28].

- **Modulation of lipid metabolism**: DHB exerts favorable effects on lipid profiles by downregulating HMG-CoA reductase, promoting LDL receptor expression, reducing triglyceride and LDL levels, and increasing HDL levels. These lipid-modulating actions contribute to cardiovascular protection in individuals with metabolic syndrome [29-30].

- **Anti-inflammatory and Antioxidant effects**: DHB also inhibits nuclear factor kappa which is considered as a key transcription factor involved in chronic inflammation. This leads to reduced expression of pro-inflammatory cytokines (e.g., TNF-α, IL-6), lower oxidative stress markers (ROS, MDA), and protection of endothelial and hepatic tissues. These actions are crucial in slowing disease progression in conditions like type 2 diabetes and atherosclerosis [31-33].

- **Enhancement of GLP-1 Secretion and Gut Hormones:** Emerging evidence suggests that DHB stimulates glucagon-like peptide-1 (GLP-1) release, which enhances: Insulin secretion, satiety signals, and gut-brain axis regulation. This mechanism not only aids in glycemic control but also supports weight loss and appetite regulation [34-36].

- **Support for Gut Microbiota Balance:** Although DHB bypasses microbial conversion, it still influences gut health by promoting beneficial SCFA-producing bacteria, reducing pathogenic microbial metabolite, and supporting gut barrier integrity. These effects make DHB beneficial in metabolic endotoxemia, inflammation, and microbiota-related insulin resistance [1,16, 27].



Figure 3: Mechanism of Action of Dihydroberberine (DHB)

Clinical Applications and Therapeutic Benefits of Dihydroberberine (DHB)

With its superior bioavailability, metabolic activity, and safety profile, Dihydroberberine (DHB) has emerged as a promising intervention for several chronic metabolic and cardiometabolic disorders [37]. Early-stage human trials and preclinical models have demonstrated that DHB matches or exceeds the clinical performance of berberine but with greater patient compliance and tolerability [38-40]. Below are the primary areas where DHB shows therapeutic promise:

1. Type 2 Diabetes and Insulin Resistance: Dihydroberberine (DHB) has proved significant glucose-lowering effects in both clinical and preclinical studies. It reduces fasting blood glucose, and hemoglobin A1c (HbA1c), and improves insulin sensitivity as measured by HOMA-IR. Due to its rapid absorption and strong activation of AMPK, DHB enhances glucose uptake in skeletal muscle and inhibits hepatic glucose production. In some rodent models, it has even matched or surpassed the glycemic control seen with metformin [5,13,27,40,50,36].

2. Dyslipidemia and Cardiovascular Risk: DHB effectively lowers LDL cholesterol, triglycerides, and total cholesterol, while modestly increasing HDL levels. These lipid-regulating effects contribute to a reduction in cardiovascular risk, particularly in individuals with metabolic syndrome. Its ability to influence lipid metabolism makes it a valuable tool for managing dyslipidemia alongside other metabolic conditions [20,21,33,41].

3. Non-Alcoholic Fatty Liver Disease (NAFLD): DHB has shown promise in managing NAFLD by reducing hepatic fat accumulation and improving liver function markers such as ALT and AST. It also decreases oxidative stress in liver tissue. These effects are largely mediated by AMPK activation and DHB's anti-inflammatory properties, making it a potential therapeutic candidate for both NAFLD and NASH [21,23,42,43].

4. Obesity and Weight Management: In metabolic studies, DHB has been linked to reductions in visceral fat, enhanced energy expenditure, and improved satiety through GLP-1 stimulation. These mechanisms support its use in weight loss interventions, especially in insulin-resistant populations. Its metabolic impact on both energy regulation and appetite makes it a dual-action agent in weight management [9,23,32,40].

5. Polycystic Ovary Syndrome (PCOS): Though research is still emerging, DHB shows potential benefits for women with PCOS by improving insulin sensitivity, reducing hyperinsulinemia, and normalizing lipid levels. These actions

address key metabolic disturbances common in PCOS and position DHB as a non-hormonal, metabolic adjunct therapy in this population.

6. Inflammatory and Oxidative Stress Disorders: DHB exhibits potent anti-inflammatory and antioxidant activity by inhibiting NF-κB, decreasing pro-inflammatory cytokines (TNF-α, IL-6), and reducing reactive oxygen species (ROS). These effects suggest its potential to mitigate chronic low-grade inflammation seen in metabolic endotoxemia, vascular dysfunction, and other oxidative stress-related disorders [38,44].

Table No. 3: Clinical Applications and Benefits of Dihydroberberine (DHB)

Therapeutic Area	Clinical Effects	References
Type 2 Diabetes and Insulin Resistance	Decreased fasting glucose, decreased HbA1c, increased insulin sensitivity	[5], [13], [27], [40], [50]
Dyslipidemia and Cardiovascular Risk	Decreased LDL, decreased triglycerides, increased HDL, decreased total cholesterol.	[20], [21], [33], [49]
Non-Alcoholic Fatty Liver Disease (NAFLD)	Decreased liver fat, decreased ALT/AST, decreased oxidative stress markers	[21], [23], [44], [46]
Obesity and Weight Management	Decreased body weight and visceral fat, increased GLP-1, increased energy expenditure	[9], [23], [32], [40]
Polycystic Ovary Syndrome (PCOS)	Increased insulin sensitivity, decreased hyperinsulinemia, improved lipid profile	[33], [40], [49]
Inflammatory and Oxidative Stress Disorders	Decreased NF-Î°B, decreased TNF-Î±/IL-6, decreased ROS, decreased systemic inflammation.	[38], [49]

Formulations, Delivery Systems, and Commercial Applications

Dihydroberberine (DHB) is a more bioavailable compound as compared to berberine and it has been optimized through various delivery systems such as micellar, liposomal, and nanocarrier formulations [45]. This approach is known to enhance solubility, stability, and intestinal absorption by reducing oxidation and also improving therapeutic consistency [46]. To preserve the activity, There are various products that are available commercially like GlucoVantage®, which claims enhanced GLP-1 response and glycemic control, and GlucoSober®, which supports lipid and HbA1c balance. These formulations are widely available as dietary supplements and are backed by emerging clinical trials and are increasingly used in functional and integrative medicine [47]. As evidence grows, DHB continues to evolve as a promising therapeutic tool in metabolic health management.

Safety and Tolerability of Dihydroberberine

Dihydroberberine (DHB) has shown a strong safety profile in both preclinical studies and early human trials, with significantly improved gastrointestinal tolerability compared to traditional berberine. One of the most common limitations of berberine supplementation has been its dose-dependent side effects—such as bloating, cramping, diarrhea, and nausea—largely due to poor intestinal absorption and microbial interaction in the gut. DHB, with its superior bioavailability and lower required dosing, circumvents these issues by delivering therapeutic effects more efficiently and with less gastrointestinal burden [7, 26, 31, 39].

Figure 4: Clinical Safety Profile of Dihydroberberine

In human studies, DHB at doses ranging from 100 to 300 mg/day has been well tolerated, with minimal adverse effects reported. No significant hepatotoxicity, nephrotoxicity, or cardiovascular abnormalities have been observed [48]. Furthermore, DHB does not interfere with liver enzyme function or renal clearance at standard doses, making it suitable for long-term metabolic therapy in a variety of populations, including individuals with insulin resistance, NAFLD, and metabolic syndrome [49]. Additionally, DHB appears to have minimal interaction with drug-metabolizing enzymes, reducing the risk of drug-supplement interactions commonly seen with polypharmacy in metabolic patients. Its favorable safety margin supports its use not only in stand-alone interventions but also as part of combination therapy alongside pharmaceuticals or other nutraceuticals.

Overall, the current evidence supports DHB as a well-tolerated, low-risk therapeutic agent, suitable for chronic use in the management of metabolic disorders. However, large-scale, long-term clinical trials are still warranted to fully validate its safety in diverse patient populations [50].

Table No.4 : Safety and Tolerability profile of Dihydroberberine (DHB)

Parameter	Dihydroberberine (DHB)	References
Typical Dose Range	100-300 mg/day	[5], [7], [31]
Gastrointestinal Tolerance	High (minimal GI distress compared to berberine)	[7], [26], [39]
Liver Function Impact	No significant effect on ALT/AST at standard doses	[31], [49]
Renal Safety	No evidence of nephrotoxicity	[31], [49]
Cardiovascular Safety	No adverse cardiovascular outcomes observed	[49]
Drug Interaction Risk	Low (minimal CYP450 interaction)	[7], [39]
Suitability for Long-term Use	Suitable for chronic metabolic therapy	[31], [49]
Reported Adverse Effects	Rare; mild digestive upset in sensitive individuals	[7], [39]

Conclusion and Future Directions

Dihydroberberine (DHB) represents a significant advancement in the field of natural therapeutics, offering a biologically optimized and clinically relevant alternative to traditional berberine. By overcoming the critical limitation of poor bioavailability, DHB achieves greater systemic exposure, more consistent therapeutic outcomes, and improved patient compliance—even at lower doses. Its ability to activate AMPK, regulate lipid and glucose metabolism, and reduce inflammation and oxidative stress makes it a powerful multifaceted tool in the management of metabolic disorders such as type 2 diabetes, dyslipidemia, obesity, NAFLD, and PCOS.

In addition to its mechanistic strengths, DHB's excellent safety profile, improved gastrointestinal tolerance, and versatility in advanced delivery systems enhance its real-world applicability. Commercial formulations are already demonstrating clinical promise, and early-phase trials suggest strong potential for broader use in both preventive and therapeutic settings.

As scientific and clinical interest in DHB continues to grow, future research should focus on long-term safety, comparative efficacy with standard pharmacotherapies, and its role in combination treatment strategies. Overall, DHB stands as a compelling example of how modern science can refine and elevate traditional botanicals to meet contemporary health challenges—ushering in a new era of precision nutraceuticals.

Acknowledgment

We proudly acknowledge M R Healthcare Pvt. Ltd., in technical collaboration with Indian Herbs Extractions, a leading innovator in herbal extraction and phytochemical manufacturing. With nearly three decades of dedicated expertise, Indian Herbs Extractions has established itself as a globally trusted name in producing Berberine HCL JP, Dihydroberberine, and their derivatives, along with a wide spectrum of standardized herbal extracts.

Their advanced, solvent-free extraction process from the roots of *Berberis aristata* ensures high-purity, pharmaceutical-grade compounds that meet stringent quality standards. This unique method results in products that are not only safe and environmentally friendly but also recognized among the best and most premium *Berberis*-derived phytochemicals worldwide.

The commitment of both organizations to precision, quality, and batch-to-batch consistency has significantly strengthened the scientific rigor and reliability of our research. Their renowned specialization in Berberine- and Dihydroberberine-based formulations continues to set industry benchmarks, and we are deeply grateful for their valuable support, which has played a key role in enhancing the quality, reproducibility, and global relevance of our work.

References

1. Chang C, Roh YS, Du M, Kuo YC, Zhang Y, Hardy M, et al. Differences in metabolite profiles of dihydroberberine and micellar berberine in Caco-2 cells and humans: a pilot study. Int J Mol Sci. 2024;25(11):5625.
2. Chang C, Solnier J, Gahler R, et al. Pilot pharmacokinetic trial: DHB vs micellar berberine; improved human bioavailability. Int J Mol Sci. 2024;25(11):5625.
3. Roh YS, Du M, Kuo YC, et al. In vitro/in vivo metabolic profiling of DHB. Int J Mol Sci. 2024;25(11):5625.
4. Bonerge Life Science. Bonerge initiates human clinical trials for ultra-pure dihydroberberine (GlucoSober®). Business Wire. 2024 Jul 31.
5. NNB Nutrition. GlucoVantage® dihydroberberine enhances GLP-1 and insulin sensitivity in human subjects. NNB Nutrition Report. 2024.
6. Hanson B, Broer H. The future of metabolic wellness starts with dihydroberberine. Healthmasters Blog. 2025 May 8.
7. Supplement Clarity. Dihydroberberine: benefits, side effects, and optimal dosage. 2024 Oct 31.
8. Healthspan Review. Dihydroberberine: metabolic regulation and cellular senescence. 2024.
9. Endurance-Research. Dihydroberberine: disruptor in weight management and metabolic health. 2025 Mar 5.
10. Wang K, Feng X, Chai L, Cao S, Qiu F. Metabolic profiling and pharmacokinetics of dihydroberberine in rats. Xenobiotica. 2017;47(9):831–9.
11. Turner N, Li JY, Gosby A, To SWC, Cheng Z, Miyoshi H, et al. Berberine and DHB regulate glucose and lipid metabolism via AMPK. Diabetes. 2008;57(5):1414–8.
12. MDPI Nutrients. Absorption kinetics of berberine and dihydroberberine in humans. Nutrients. 2022;14(1):124.
13. ICH GCP. Clinical trial NCT05021341: Bioavailability of berberine and dihydroberberine (BBD). 2021.
14. Guy's Pharmacy Blog. DHB: the supercharged berberine for better health. 2024 Aug 12.
15. NutriAvenue. DHB vs berberine: benefits for blood sugar and absorption. 2023–2024.
16. MDPI study – human Caco-2/DHB metabolism. Int J Mol Sci. 2024;25(11):5625.
17. Optimal synthesis conditions for 8,13 disubstituted DHB derivatives. RSC New J Chem. 2024;48:268–80.
18. DHB derivative improves AMPK-mediated insulin resistance in rodents. Diabetes. 2008;57:1414–8.

19. PricePlow Blog. Natural GLP-1 revolution: GlucoVantage improves GLP-1 by 95%. 2024.
20. Therapeutic effect of berberine on metabolic diseases: preclinical/clinical base. Phytother Res. 2020.
21. Berberine as multi-target obesity agent: pharmacokinetics and clinical evidence. BMC Eur J Med Res. 2025 May 12.
22. Mahshid et al. Dual-trigger berberine chloride nanocarrier release. arXiv. 2024 Jan.
23. Kong Y, et al. Progress of anti-obesity effects of berberine and its metabolite derivatives: a review. arXiv. 2025 Jan.
24. Horsfieldia iryaghedhi anti-inflammatory study (controls via docking). arXiv. 2024 May.
25. Tinospora cordifolia in silico SARS-CoV-2 study (includes berberine). arXiv. 2020 Jul.
26. Endurance-Research. Meta-analysis: low dose DHB as tolerable alternative. 2024.
27. NNB Nutrition study: DHB improves insulin sensitivity and gut hormone profile. 2024.
28. Supplement Clarity. DHB absorption 3.25–4.8× better in rats. 2024.
29. MDPI Nutrients. DHB AUC significantly higher than BBR. 2022.
30. Guy's Pharmacy. DHB absorbed 5–10× better than BBR; AMPK activation. 2024.
31. Healthmasters. DHB provides higher plasma BBR concentration at lower doses. 2025.
32. PricePlow. DHB enhances GLP-1; potential metformin alternative. 2024.
33. Endurance-Research. DHB activates AMPK and gene expression lipid/glucose pathways. 2025.
34. Int J Mol Sci. Pilot study: DHB human and cell metabolism comparison. 2024.
35. Xenobiotica. Rat PK study: DHB metabolism and tissue distribution. 2017.
36. Diabetes. Improvement in insulin resistance using DHB in rodent model. 2008.
37. Business Wire. Bonerge DHB clinical trial announcement. 2024.
38. Healthspan. DHB review on cell senescence and mTOR pathway. 2024.
39. Supplement Clarity. Side effect profile points supporting DHB use safety. 2024.
40. NNB Nutrition. GlucoVantage® human trial outcomes. 2024.
41. MDPI. Dietary study: BBR vs DHB crossover design in healthy males. Nutrients. 2022.
42. Guy's Pharmacy Blog. DHB absorption data. 2024.
43. PricePlow. Supplement review on DHB and GLP-1 results. 2024.
44. Endurance-Research. 2025 weight management industry report.
45. RSC journal. Methods paper on NBF-modified DHB yield optimization. 2024.
46. arXiv. Obesity berberine review includes DHB mention. 2025.
47. arXiv. Nanocarrier drug release tech includes DHB form. 2024.
48. arXiv. Plant extract docking includes berberine analogs. 2020.
49. BMC. Obesity pharmacology safety review linked to DHB potential. 2025.
50. ClinicalTrials.gov. Clinical trial record NCT05021341: DHB impact on glycemia. 2021.